Lowers the risk of hospitalization for heart failure. ANDA 211156, held by Inventia. Dapagliflozin.
As of Nov 15, 2026, ANDA 211156 (Dapagliflozin), held by Inventia, was first approved by FDA on Apr 6, 2026, with 1 approved supplement and 0 published complete response letters.
Dapagliflozin tablets are indicated: To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established CV disease or multiple CV risk factors. As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use Dapagliflozin tablets are not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. Dapagliflozin tablets are not recommended for use to improve glycemic control in patients with type 2 diabetes mellitus with an eGFR less than 45 mL/min/1.73 m 2.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 6, 2026 | Original application | Approved |
| Dapagliflozin5MG · tablet;oral | Dapagliflozin | Rx |
| Dapagliflozin10MG · tablet;oral | Dapagliflozin | Rx |
| May 28, 2026 | Supplement 3Manufacturing | Approved | None posted |
| Apr 6, 2026 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters